Table 4 Overview of the safety profile of IRd (safety population, N = 140).

From: In-class transition (iCT) of proteasome inhibitor-based therapy: a community approach to multiple myeloma management

  

Age

Frailty status

TEAEs, n (%)

Overall (N = 140)

<75 years (n = 81)

≥75 years (n = 59)

Non-frail (n = 54)

Frail (n = 86)

Any TEAE

137 (97.9)

79 (97.5)

58 (98.3)

52 (96.3)

85 (98.8)

 Treatment-related

115 (82.1)

69 (85.2)

46 (78.0)

47 (87.0)

68 (79.1)

Grade ≥3 TEAEs

96 (68.6)

56 (69.1)

40 (67.8)

33 (61.1)

63 (73.3)

 Treatment-related

52 (37.1)

27 (33.3)

25 (42.4)

19 (35.2)

33 (38.4)

Serious TEAEs

62 (44.3)

34 (42.0)

28 (47.5)

21 (38.9)

41 (47.7)

 Treatment-related

18 (12.9)

10 (12.3)

8 (13.6)

8 (14.8)

10 (11.6)

TEAE leading to drug modificationa

93 (66.4)

54 (66.7)

39 (66.1)

33 (61.1)

60 (69.8)

TEAE leading to drug discontinuationa

28 (20.0)

16 (19.8)

12 (20.3)

14 (25.9)

14 (16.3)

On-study deathsb

4 (2.9)

2 (2.5)

2 (3.4)

1 (1.9)

3 (3.5)

  1. IRd ixazomib-lenalidomide-dexamethasone, TEAE treatment emergent adverse event.
  2. aModifications and discontinuations for any of the three study drugs.
  3. bOccurring <30 days after last dose; deaths were due to unrelated end-stage renal disease, treatment-related pneumonia, disease-related complications, and unknown (N = 1 each).
Back to article page